

Adamas Pharmaceuticals Inc  
 Form 4  
 March 24, 2015

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2015  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
 Went Gregory T

2. Issuer Name and Ticker or Trading Symbol  
 Adamas Pharmaceuticals Inc  
 [ADMS]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)  
 03/20/2015

Director  10% Owner  
 Officer (give title below)  Other (specify below)  
 Chief Executive Officer

C/O ADAMAS PHARMACEUTICALS, INC., 1900 POWELL ST., SUITE 750

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

EMERYVILLE, CA 94608

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|---|
|                                 |                                      |  |                                | (A) or (D)<br>Code V Amount (D) Price                             |   |  |   |
| Common Stock                    | 03/20/2015                           |  | M                              | 100 A \$ 1.875  | 10,108 <sup>(1)</sup>   | D  |   |
| Common Stock                    | 03/20/2015                           |  | S                              | 100 D \$ 18   | 10,008 <sup>(1)</sup>   | D  |   |
| Common Stock                    | 03/20/2015                           |  | S                              | 200 D \$ 18   | 405,980 <sup>(1)</sup>  | I  | Gregory T Went & Marjorie S Went tees Went Family     |

|              |        |   |  |
|--------------|--------|---|--|
| Common Stock | 6,666  | I | Living Trust dtd 03/24/11<br>Gregory T Went Cust - Bridget Went Under CA Uniform Transfers to Minors Act |
| Common Stock | 6,666  | I | Gregory T Went Cust - Cora Went Under CA Uniform Transfers to Minors Act                                 |
| Common Stock | 80,000 | I | Gregory T Went & Marjorie S Went ttees 2012 Irr Trust FBO Bridget Elise Went                             |
| Common Stock | 80,000 | I | Gregory T Went & Marjorie S Went ttees 2012 Irr Trust FBO Cora Margaret Went                             |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: Adamas Pharmaceuticals Inc - Form 4

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | 8. Price or Value of Underlying Securities (Instr. 3 and 4) |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|---|
|--|--|--------------------------------------|--|--------------------------------|---|--|---|---|

|                             |          |            |  | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title        | Amount or Number of Shares |    |
|-----------------------------|----------|------------|--|------|---|-----|-----|------------------|-----------------|--------------|----------------------------|----|
| Stock Option (Right to Buy) | \$ 1.875 | 03/20/2015 |  | M    |   |     |     | (2)              | 09/12/2016      | Common Stock | 100                        | \$ |

## Reporting Owners

| Reporting Owner Name / Address   | Relationships |           |                         |       |
|--|---------------|-----------|-------------------------|-------|
|  | Director      | 10% Owner | Officer                 | Other |
| Went Gregory T<br>C/O ADAMAS PHARMACEUTICALS, INC.<br>1900 POWELL ST., SUITE 750<br>EMERYVILLE, CA 94608 | X             | X         | Chief Executive Officer |       |

## Signatures

/s/Grace Shin, as  
Attorney-in-Fact

03/24/2015

\*\*Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- (2) This option is fully vested and exercisable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.